Mylan says U.S. customers may have trouble getting EpiPens

Mylan reported on Tuesday that U.S. consumers may have difficulty getting EpiPen prescriptions filled after manufacturing problems constrained supply. Food allergy groups have been pressing U.S.

Mylan reported on Tuesday that U.S. consumers may have difficulty getting EpiPen prescriptions filled after manufacturing problems constrained supply. Food allergy groups have been pressing U.S. regulators for answers after more than 400 people in 45 states indicated that they have had trouble getting prescriptions filled for the potentially lifesaving autoinjectors of the drug epinephrine. FDA said it does not believe there is a shortage. "Mylan has continued to report adequate supply of EpiPens in the U.S.," said FDA press officer Theresa Eisenman. "Occasionally pharmacies report local supply issues, however these are usually temporary and involve distribution issues and resolve when the pharmacy is able to reorder from their distributor." Last week, the American Society of Health-System Pharmacists added EpiPen to its list of drugs in short supply in the United States. Mylan on Tuesday said it notified FDA a few months ago of "intermittent supply constraints" due to delays at its manufacturing partner Pfizer. The company said it is currently receiving "continual" supply from Pfizer unit Meridian Medical Technologies, which produces all EpiPens sold globally at a single plant near St. Louis.